NICE is now halfway through the drugs it is considering from the CDF and so far all have been recommended for routine NHS use. Companies have provided discounts and in some cases additional evidence meaning the drugs can be considered cost effective for routine NHS use.
The CDF was established by the Government in 2010 as a temporary solution to help patients access cancer drugs that were not widely available on the NHS. However the Fund quickly exceeded its original £200 million budget.
In 2016 reforms were put in place which required NICE to carry out appraisals for the drugs in the existing Fund and all newly licensed cancer drugs.
Two drugs from the CDF have today been recommended for routine use, bringing the total to 14 CDF drugs approved so far from the 24 NICE will look at.
Sir Andrew Dillon, chief executive at NICE, said: “The system is working well.
“Companies are cooperating well with our reviews and the good news for patients is that more cancer drugs than ever are being recommended for routine use.
“As drugs move off the CDF, we free up funding for new drugs coming down the pipeline, so patients will have faster access to promising cancer drugs and the NHS makes the most of its resources.”
Appraisals continue for the remaining drugs. None have been rejected in final guidance.
Two bowel cancer drugs were approved in draft guidance on Thursday 2 March.
Cetuximab (Erbitux, Merck Serono) and panitumumab (Vectibix, Amgen) are now recommended as options for certain people with bowel cancer.
Both drugs were placed on the CDF list after changes to their licence meant NICE’s original guidance was no longer valid. For the review both companies provided new evidence as well confidential discounted prices which meant NICE could recommend them both.
Deborah Alsina MBE, chief executive at Bowel Cancer UK, said: “This announcement is very welcome as currently less than one in ten people with advanced bowel cancer survive for five years or more. Ongoing access to these medicines is very important as it offers hope for longer term survival and for some even the chance of a full remission. The advancement of targeted therapies is an important development in the treatment of people with bowel cancer and is part of an ongoing shift from everyone receiving the same treatment to people beginning to receive treatment right for them based on their genetic profile.”
NICE expects to publish final guidance for cetuximab and panitumumab in April 2017.